Pembrolizumab + Lenvatinib + Placebo for lenvatinib
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Oct 23, 2019 → Mar 29, 2024
NCT ID
NCT04676412About Pembrolizumab + Lenvatinib + Placebo for lenvatinib
Pembrolizumab + Lenvatinib + Placebo for lenvatinib is a phase 3 stage product being developed by Eisai for Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04676412. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04889118 | Phase 3 | Completed |
| NCT04676412 | Phase 3 | Completed |
| NCT03898180 | Phase 3 | Completed |
| NCT03829332 | Phase 3 | Completed |
| NCT03820986 | Phase 3 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer